Trials / Completed
CompletedNCT00826514
An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis
A PHASE 2, 16 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED, PARALLEL GROUP PROOF-OF-CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF PAIN ASSOCIATED WITH CHRONIC ABACTERIAL PROSTATITIS
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether tanezumab is effective in the treatment of pain associated with chronic prostatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tanezumab | Intravenous, 20 mg, single dose. |
| DRUG | Placebo | Intravenous placebo, single dose |
Timeline
- Start date
- 2009-03-25
- Primary completion
- 2010-01-11
- Completion
- 2010-03-17
- First posted
- 2009-01-22
- Last updated
- 2021-05-13
- Results posted
- 2021-05-13
Locations
44 sites across 5 countries: United States, Canada, France, Sweden, Switzerland
Source: ClinicalTrials.gov record NCT00826514. Inclusion in this directory is not an endorsement.